Patient-Reported Outcomes from the Phase 3 ADAURA Trial of Adjuvant Osimertinib in EGFRm NSCLC

Roy S. Herbst, MD, PhD, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) on patient-reported outcomes from ADAURA (NCT02511106), a phase 3 trial of osimertinib as adjuvant therapy in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC).

Roy S. Herbst, MD, PhD, discusses data from the following presentation:

• Patient-Reported Outcomes From ADAURA: Osimertinib as Adjuvant Therapy in Patients With Resected EGFR mutated (EGFRm) NSCLC. (Majem, WCLC 2020, abstract OA06.03)

  • In ADAURA, patients were disease-free following surgery, with or without prior adjuvant chemotherapy.

    • Health-related quality of life (HRQOL) was measured until disease recurrence, treatment completion (3 years), or treatment discontinuation (whichever came first).

    • No HRQOL data were collected after treatment discontinuation due to disease recurrence or other discontinuation criteria.

  • Baseline SF-36 PCS and MCS T-scores were comparable in the osimertinib and placebo arms (range, 46-47) and only slightly lower than the mean T-scores in the general population.

  • There were no clinically meaningful differences between osimertinib and placebo from baseline to week 96 for PCS, MCS, or health domain T-scores.

  • There were no differences between osimertinib and placebo in TTD of SF-36 PCS, MCS. or health domains.

  • Overall, HRQOL was maintained during adjuvant osimertinib treatment with no clinically meaningful differences vs placebo, despite prolonged treatment.

  • Adjuvant osimertinib, with or without prior adjuvant chemotherapy, provided a significant disease-free survival benefit without affecting HRQOL in completely resected, patients with stage IB-IIIA EGFRm NSCLC. This further supports osimertinib as an effective new treatment strategy in this setting.